<![CDATA[Introduction: Platinum-based chemotherapy remains the standard first-line therapy for advanced lung cancer; however, its administration is frequently associated with various hematologic and non-hematologic toxicities that may affect patient outcomes and quality of life. Understanding the toxicity profile of platinum-based regimens is essential for optimizing supportive care and treatment monitoring. Objective: This study aimed to analyze the association between platinum-based chemotherapy regimens and the incidence of chemotherapy-related toxicities in lung cancer patients in Medan. Methods: A retrospective study was conducted using medical records of lung cancer patients treated at Prof. dr. Chairuddin P. Lubis Universitas Sumatera Utara Hospital and Adam Malik Hospital from January 2023 to June 2025. Sequential sampling was applied to patients who had received at least two cycles of platinum-based chemotherapy. Hematologic and non-hematologic toxicities were assessed and graded according to the highest toxicity level observed during treatment. Data were analyzed using univariate analysis and Chi-square tests with SPSS version 29. Results: A total of 134 patients were included, predominantly male (85.07%) and aged over 60 years (48.51%). Adenocarcinoma was the most common subtype (57.46%), while carboplatin-based regimens were more frequently administered (75.37%). The most common hematologic toxicity was anemia (76.12%), whereas myalgia (95.52%), pulmonary complications (87.31%), nausea/vomiting (85.82%), and alopecia (75.37%) were the most frequent non-hematologic toxicities. Significant associations were identified between platinum-based chemotherapy regimens and the occurrence of diarrhea (p=0.011) and oral mucositis (p=0.008). Conclusion: Platinum-based chemotherapy in lung cancer patients is associated with substantial hematologic and non-hematologic toxicities, particularly myalgia and pulmonary complications. Carboplatin regimens were more commonly used and generally showed a milder toxicity profile compared with cisplatin. Early monitoring and regimen-specific supportive management are recommended to reduce chemotherapy-related complications.]]>
